Agenus to present melanoma data at ASCO 2026
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Agenus Inc (AGEN)
Agenus Inc stock price live, this page displays NASDAQ AGEN stock exchange data. View the AGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Agenus Inc real time stock price chart below.
What Is the Agenus Inc Stock Price Today?
The Agenus Inc stock price today is 3.760.
What Is the Stock Symbol for Agenus Inc?
The stock symbol for Agenus Inc is "AGEN."
What Stock Exchange Does Agenus Inc Trade On?
Agenus Inc is listed and trades on the NASDAQ stock exchange.
Is Agenus Inc a Good Stock to Buy?
Determining whether Agenus Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGEN quote. (ISIN: US00847G8042) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
What Is the Agenus Inc Stock Price Today?
The Agenus Inc stock price today is 3.760.
What Is the Stock Symbol for Agenus Inc?
The stock symbol for Agenus Inc is "AGEN."
What Stock Exchange Does Agenus Inc Trade On?
Agenus Inc is listed and trades on the NASDAQ stock exchange.
Is Agenus Inc a Good Stock to Buy?
Determining whether Agenus Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGEN quote. (ISIN: US00847G8042) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
Fair Value
An estimate of a Agenus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.750
3.965
52 wk Range
2.630
7.340
AGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Agenus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.7503.965
52 wk Range
2.6307.340
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AGEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Agenus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
15.500
Upside
+312.23%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Form PRE 14A Agenus Inc. For: 20 April
- Investing.com
- Agenus to present melanoma data at ASCO 2026
- Investing.com
- Form PRE 14A Agenus Inc. For: 20 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Agenus Inc Earnings Call Summary for Q2/2025
- Agenus pursuing accelerated approval for BotVal immunotherapy; stock up 154% in 6 months, trading at $4.66
- Collaborating with Zydis Corporation to enhance manufacturing; initiating Phase III BATMAN trial with Canadian Cancer Trials Group
- Focus on colorectal cancer treatment, developing second-generation CTLA-4 immunotherapy and iNKT cell technology
- Preparing for ESMO presentation; CEO emphasizes ambitious goals beyond incremental improvements
- Revenue and EPS not disclosed; ongoing discussions for potential financing transactions noted
Last Updated: 12/09/2025, 16:40
Read Full TranscriptCompare AGEN to Peers and Sector
Metrics to compare | AGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1,429.5x | −1.2x | −0.4x | |
PEG Ratio | −14.30 | −0.25 | 0.00 | |
Price/Book | −0.5x | 2.7x | 2.6x | |
Price / LTM Sales | 1.3x | 7.8x | 3.2x | |
Upside (Analyst Target) | 312.2% | 122.6% | 46.7% | |
Fair Value Upside | Unlock | 19.3% | 7.6% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 15.500
(+312.23% Upside)
Earnings
Latest Release
Mar 16, 2026
EPS / Forecast
-0.31 / -0.27
Revenue / Forecast
34.2M / --
People Also Watch
FAQ
What Is the Agenus (AGEN) Stock Price Today?
The Agenus stock price today is 3.760 USD.
What Stock Exchange Does Agenus Trade On?
Agenus is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Agenus?
The stock symbol for Agenus is "AGEN."
What Is the Agenus (AGEN) Afterhours Price Today? (Afterhours variable test: 3.880) Current Date: Apr 24, 2026
After hours price: 3.880. After hours price change (units): 0.120. Price change percentage: 3.190%
What Is the Agenus Market Cap?
As of today, Agenus market cap is 144.380M USD.
What Is Agenus's Earnings Per Share (TTM)?
The Agenus EPS (TTM) is -0.003.
From a Technical Analysis Perspective, Is AGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Agenus Stock Split?
Agenus has split 2 times.
How Many Employees Does Agenus Have?
Agenus has 81 employees.
What is the current trading status of Agenus (AGEN)?
As of Apr 24, 2026, Agenus (AGEN) is trading at a price of 3.760 USD, with a previous close of 3.760 USD. The stock has fluctuated within a day range of 3.750 USD to 3.965 USD, while its 52-week range spans from 2.630 USD to 7.340 USD.
What Is Agenus (AGEN) Price Target According to Analysts?
The average 12-month price target for Agenus is 15.500 USD, with a high estimate of 23 USD and a low estimate of 8 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +312.23% Upside potential.
What Is the AGEN Premarket Price?
AGEN's last pre-market stock price is 3.865 USD. The pre-market share volume is 590.000, and the stock has decreased by 0.105, or 2.790%.
What Is the AGEN After Hours Price?
AGEN's last after hours stock price is 3.880 USD, the stock has decreased by 0.120, or 3.190%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.